Chemosensitizing effect of nordihydroguaiaretic acid and its tetra-acetylated derivative on parental and multiresistant TA3 mouse mammary adenocarcinoma cells

In Vivo

Volumn 23, Issue 6, 2009, Pages 959-967

  Plaza, Claudio ^a   Pavani, Mario ^a   Araya Maturana, Ramiro ^a   Pezoa, Jaqueline ^a   Maya, Juan Diego ^a   Morello, Antonio ^a   Becker, Maria Inés ^b   De Ioannes, Alfredo ^b   Ferreira, Jorge ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b Biosonda SA ^*  (Chile)

Author keywords

Chemosensitizing effect; Cytotoxicity; Nordihydroguaiaretic acid derivative; Tumor cell growth inhibition

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; NORDIHYDROGUAIARETIC ACID; RHODAMINE; TETRAACETYLATED NORDIHYDROGUAIARETIC ACID; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL LINE TA3; CHEMOSENSITIZATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACETYLATION; DRUG POTENTIATION; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; SURVIVAL TIME; TUMOR GROWTH;

EID: 75149121015     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Sugawara I, Akiyama S, Scheper RJ and Itoyama S: Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDRl and MRP. Cancer Lett 112: 23-31, 1997.
2. Tucci M, Quatraro C, Dammacco F and Silvestris F: Role of active drug transporters in refractory multiple myeloma. Curr Top Med Chem 9: 218-224, 2009.
3. Tao L, Liang Y, Wang F, Chen L, Yan C, Dai C and Fu L: Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemother Pharmacol: 3 March 2009. doi: 10.1007/s00280-009-0949-1
4. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA Jr and Chou TC: Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 59: 6178-6184 1999.
5. Rowe DL, Ozbay T, Bender LM and Nahta R: Nordihydro-guaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/ HER2 inhibitor in trastuzumab-resistant breast cancer. Mol Cancer Ther 7: 1900-1908, 2008.
6. Yoshida T, Shiraishi T, Horinaka M, Nakata S, Yasuda T, Goda AE, Wakada M, Mizutani Y, Miki T, Nishikawa A and Sakai T: Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis. Cancer Sci 98: 1417-1423, 2007.
7. Siddique YH, Beg T and Afzal M: Protective effect of nordihydroguaiaretic acid (NDGA) against norgestrel induced genotoxic damage. Toxicol In Vitro 20: 227-233, 2006.
8. Floriano-Sánchez E, Villanueva C, Medina-Campos ON, Rocha D, Sánchez-González DJ, Cárdenas-Rodríguez N and Pedraza-Chaverrf J: Nordihydroguaiaretic acid is a potent in vitro scavenger of peroxynitrite, singlet oxygen, hydroxyl radical, superoxide anion and hypochlorous acid and prevents in vivo ozone-induced tyrosine nitration in lungs. Free Radic Res 40: 523-533, 2006.
9. Yam-Canul P, Chirino YI, Sánchez-González DJ, Martínez-Martínez CM, Cruz C, Villanueva C and Pedraza-Chaverri J: Nordihydroguaiaretic acid attenuates potassium dichromate-induced oxidative stress and nephrotoxicity. Food Chem Toxicol 46: 1089-1096, 2008.
10. Deshpande VS and Kehrer JP: Oxidative stress-driven mechanisms of nordihydroguaiaretic acid-induced apoptosis in FL5.12 cells. Toxicol Appl Pharmacol 214: 230-236, 2006.
11. Wu X, Biswal SS and Kehrer JP: Roles of 5-lipoxygenase activating protein in cell proliferation and apoptosis. Cell Biol Toxicol 19: 135-43, 2003.
12. Tong WG, Ding XZ, Witt RC and Adrian TE: Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Ther 1: 929-935, 2002.
13. Ansar S, Iqbal M and Athar M: Nordihydroguaiaretic acid is a potent inhibitor of ferric-nitrilotriacetate-mediated hepatic and renal toxicity, and renal tumour promotion, in mice. Carcinogenesis 20: 599-606, 1999.
14. Hagmann W: Lipoxygenase in human tumor cells. Pathol Oncol Res 3: 83-88, 1997.
15. Timár J, Rásó E, Döme B, Li L, Grignon D, Nie D, Honn KV and Hagmann W: Expression, subcellular localization and putative function of platelet-type 12-lipoxygenase in human prostate cancer cell lines of different metastatic potential. Int J Cancer 87: 37-43 2000.
16. Shureiqi I and Lippman SM: Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 61: 6307-6312, 2001.
17. Peng Q, Moan J and Cheng LS: The effect of glucose administration on the uptake of photofrin II in a human tumor xenograft. Cancer Lett 58: 29-35, 1991.
18. Fones E, Amigo H, Gallegos K, Guerrero A and Ferreira J: t-Butyl-4-hydroxyanisole as an inhibitor of tumor cell respiration. Biochem Pharmacol 38: 3443-3451, 1989.
19. Pavani M, Fones E, Oksenberg D, Garcia M, Hernandez C, Cordano G, Muñoz S, Mancilla J, Guerrero A and Ferreira J: Inhibition of tumoral cell respiration and growth by nordihydroguaiaretic acid. Biochem Pharmacol 48: 1935-1942, 1994.
20. Plaza C, Pavani M, Faundez M, Maya JD, Morello A, Becker MI, De Ioannes A, Cumsille MA and Ferreira J: Inhibitory effect of nordihydroguaiaretic acid and its tetra-acetylated derivative on respiration and growth of adenocarcinoma TA3 and its multiresistant variant TA3MTX-R. In Vivo 22: 353-361, 2008.
21. Arasaki K, Tani K, Yoshimori T, Stephens DJ and Tagaya M: Nordihydroguaiaretic acid affects multiple dynein-dynactin functions in interphase and mitotic cells. Mol Pharmacol 71: 454-460, 2007.
22. Billinsky JL, Marcoux MR and Krol ES: Oxidation of the lignan nordihydroguaiaretic acid. Chem Res Toxicol 20: 1352-1358, 2007.
23. Chang CC, Liang YC, Klutz A, Hsu CI, Lin CF, Mold DE, Chou TC, Lee YC and Huang RC: Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel. Cancer Chemother Pharmacol 58: 640-653, 2006.
24. Cordano G, Pezoa J, Muñoz S, Rivera E, Medina J, Núñez-Vergara LJ, Pavani M, Guerrero A and Ferreira J: Inhibitory effect of vanillin-like compounds on respiration and growth of adenocarcinoma TA3 and its multiresistant variant TA3-MTX-R. Eur J Pharm Sci 16: 255-263, 2002.
25. Frey C, Pavani M, Cordano G, Muñoz S, Rivera E, Medina J, Morello A, Maya JD and Ferreira J: Comparative cytotoxicity of alkyl gallates on mouse tumor cell lines and isolated rat hepatocytes. Comp Biochem Physiol A Mol Integr Physiol 146: 520-527, 2007.
26. Moreadith RW and Fiskum G: Isolation of mitochondria from ascites tumor cells permeabilized with digitonin. Anal Biochem 137: 360-367, 1984.
27. Singh G and Moorehead R: Mitochondria as a target for combination cancer chemotherapy. Int J Oncol 1: 825-829, 1992.
28. Hait W, Gesmonde JF, Murren JR, Yang J, Chen H and Reiss M: Terfenadine (seldane®): a new drug for restoring sensitivity to multidrug resistant-cancer cells. Biochem Pharmacol 45: 401-406, 1993.
29. Ganapathi R, Grabowski D, Rouse W and Riegler F: Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells. Cancer Res 44: 5056-5061, 1984.
30. Altenberg GA, Young G, Horton J, Glass D, Belli JA and Reuss: Changes in intra- or extracellular pH do not mediate P-glycoprotein-dependent multidrug resistance. Proc Natl Acad Sci USA 90: 9735-9738, 1993.
31. Rogan AM, Hamilton TC and Young RC: Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994-996, 1984.
32. Dean M, Fojo T and Bates S: Tumor stem cells and drug resistance. Nat Rev Cancer 5: 275-284, 2005.
33. Meyer AN, McAndrew CW and Donoghue DJ: Nordihydro-guaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells. Cancer Res 68: 7362-7370, 2008.
34. Yuneva M: Finding an "Achilles' heel" of cancer: the role of glucose and glutamine metabolism in the survival of transformed cells. Cell Cycle 7: 2083-2089, 2008.
35. Mathupala SP, Ko YH and Pedersen PL: Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin Cancer Biol 19: 17-24, 2009.